Major Depressive Disorder: 68-Market Analysis and Sales Forecast - Update

Major Depressive Disorder: 68-Market Analysis and Sales Forecast - Update

Summary

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.

GlobalData estimated that drug sales for MDD in 2019 were approximately $4.73 billion across the 8MM. The US market makes up the majority of total global sales, contributing $3.35 billion (70.7%) due to the large MDD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the MDD market will grow to be worth approximately $9.55 billion by 2029, at a compound annual growth rate (CAGR) of 7.3%. The US is expected to maintain its position as the market leader in 2029, increasing the proportion of global sales it accounts for to 84.7%

Across the 68 markets, sales in the MDD market were $8.8billion in 2019, growing to $14.4 billion in 2029. The eight major markets (US, France, Germany, Italy, Spain, UK, Japan and Canada) represent approximately 53.6% and 66.4% of 68-market sales in 2019 and 2029, respectively.

Scope

• Overview of major depressive disorder (MDD), including epidemiology, symptoms, diagnosis, and disease management.
• Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 8MM as well as the 68M MDD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM MDD therapeutics market in the future.= and their impact on the 68M on a macro level.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.